Charles Schwab
ARGS

Charles Schwab’s Argos Therapeutics, Inc. ARGS Stock Holding History

Charles Schwab’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,110
Closed -$11K – 3229
2017
Q1 		$11K Hold
1,110
– – ﹤0.01% 3054
2016
Q4 		$109K Hold
1,110
– – ﹤0.01% 3036
2016
Q3 		$111K Hold
1,110
– – ﹤0.01% 3006
2016
Q2 		$137K Buy
+1,110
New +$148K ﹤0.01% 3024

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Charles Schwab's ARGS Position: Q2 2017 in Review

Charles Schwab sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 1,110 shares — an estimated $11K sold.

Charles Schwab first reported a position in ARGS in Q2 2016 and held it in 4 quarters. The position peaked at $137K in Q2 2016. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

  • Charles Schwab reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Charles Schwab sold 1,110 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $11K.
  • Charles Schwab first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
  • Charles Schwab's Argos Therapeutics, Inc. position peaked at $137K in Q2 2016.
  • 34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on Charles Schwab's 13F filing for Q2 2017, filed 2 Aug 2017.